Alpine Immune Sciences Treating IgA nephropathy
Alpine Immune Sciences (ALPN) announced a successful initiation of the second IgA nephropathy (IgAN) dose cohort in RUBY-3, a phase 1b/2a study in autoimmune glomerulonephritis. The safety Monitoring Committee (SMC) determined that repeat . . .
This content is for paid subscribers.
Impacting News
August 31, 2023
